Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis (URSONASH)
|ClinicalTrials.gov Identifier: NCT00470171|
Recruitment Status : Completed
First Posted : May 7, 2007
Last Update Posted : February 3, 2009
This is a phase II study with direct individual benefit. It is a randomized, double blind placebo controlled study whose aim is to evaluate the efficacy and tolerance of ursodesoxycholic acid in patients who have been diagnosed with non-alcoholic steatohepatitis.
The hepatoprotective effects of ursodesoxycholic acid may ameliorate the hepatic impairment associated with non-alcoholic steatohepatitis leading to subsequent significant decreases in transaminase elevations and non-invasive markers for hepatic fibrosis A positive response is defined as a significantly larger decrease in average ALAT levels between the time of inclusion in the study and the end of the treatment for the ursodesoxycholic acid group as compared to the placebo group.
The duration of the study will be 12 months. An end of treatment evaluation (EoT) will take place at the end of the 12th month of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Serum Levels of ALAT Transaminases Serum Markers for Fibrosis and Hepatic Inflammation||Drug: Ursodesoxycholic acid||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||98 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of Ursodesoxycholic Acid in the Management of Non-Alcoholic Steatohepatitis|
|Study Start Date :||October 2005|
|Actual Primary Completion Date :||November 2008|
|Actual Study Completion Date :||November 2008|
- A positive response is defined as a significantly larger decrease in average ALAT levels between the time of inclusion in the study and the end of the treatment for the ursodesoxycholic acid group as compared to the placebo group.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00470171
|La Pitié Salpétrière Hospital|
|Paris, France, 75013|
|Principal Investigator:||Vlad Ratziu, M.D., Ph.D.||La Pitié Salpétrière Hospital, Paris, France|